Baricitinib 2mg /天作为中重度特应性皮炎系统治疗的成本意识切入点：来自日本诊所的真实世界数据

IF 3.7 4区医学 Q1 DERMATOLOGY

Acta dermato-venereologica Pub Date : 2025-09-10 DOI:10.2340/actadv.v105.43616

Masato Mizuashi

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic.

查看原文本刊更多论文

Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta dermato-venereologica 医学-皮肤病学

CiteScore

4.90

自引率

2.80%

发文量

210

审稿时长

6-12 weeks

期刊介绍： Acta Dermato-Venereologica publishes high-quality manuscripts in English in the field of Dermatology and Venereology, dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of Review articles in special areas, as well as short Letters to the Editor to stimulate debate and to disseminate important clinical observations. Acta Dermato-Venereologica has rapid publication times and is amply illustrated with a large number of colour photographs.